IsoPlexis (NASDAQ:ISO) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of IsoPlexis (NASDAQ:ISO – Get Rating) from a hold rating to a buy rating in a research note released on Friday, Zacks.com reports. They currently have $2.25 price target on the stock.

According to Zacks, “IsoPlexis Corporation is a life science technology company which build solutions for development of curative medicines and personalized therapeutics. IsoPlexis Corporation is based in BRANFORD, Conn. “

A number of other research analysts also recently weighed in on the company. SVB Leerink reduced their target price on IsoPlexis from $20.00 to $15.00 and set an outperform rating on the stock in a report on Thursday, January 27th. Morgan Stanley reduced their target price on IsoPlexis from $17.00 to $12.00 and set an overweight rating on the stock in a report on Tuesday, February 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of Buy and an average price target of $13.31.

Shares of NASDAQ:ISO opened at $1.96 on Friday. IsoPlexis has a 1 year low of $1.62 and a 1 year high of $16.95. The company has a debt-to-equity ratio of 0.22, a quick ratio of 9.88 and a current ratio of 11.67. The stock’s 50-day moving average is $3.03 and its 200 day moving average is $6.81.

IsoPlexis (NASDAQ:ISO – Get Rating) last posted its earnings results on Wednesday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). As a group, analysts forecast that IsoPlexis will post -2.23 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Citigroup Inc. bought a new position in IsoPlexis in the 4th quarter valued at approximately $36,000. Renaissance Technologies LLC bought a new position in IsoPlexis in the 1st quarter valued at approximately $36,000. California State Teachers Retirement System bought a new position in IsoPlexis in the 4th quarter valued at approximately $43,000. Deutsche Bank AG bought a new position in IsoPlexis in the 4th quarter valued at approximately $47,000. Finally, Wells Fargo & Company MN bought a new position in IsoPlexis in the 4th quarter valued at approximately $48,000. Institutional investors own 76.49% of the company’s stock.

IsoPlexis Company Profile (Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

Read More